We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
Read MoreHide Full Article
Recursion Pharmaceuticals (RXRX - Free Report) ended the recent trading session at $3.66, demonstrating a +1.39% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.28%. Elsewhere, the Dow saw an upswing of 1.02%, while the tech-heavy Nasdaq depreciated by 0.02%.
The stock of biotechnology company has fallen by 9.07% in the past month, lagging the Medical sector's gain of 1.01% and the S&P 500's gain of 0.67%.
The investment community will be paying close attention to the earnings performance of Recursion Pharmaceuticals in its upcoming release. The company is expected to report EPS of -$0.24, up 33.33% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $8.42 million, showing a 62.57% escalation compared to the year-ago quarter.
RXRX's full-year Zacks Consensus Estimates are calling for earnings of -$0.93 per share and revenue of $42.82 million. These results would represent year-over-year changes of +35.42% and -42.66%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Recursion Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.72% downward. Currently, Recursion Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 98, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
Recursion Pharmaceuticals (RXRX - Free Report) ended the recent trading session at $3.66, demonstrating a +1.39% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.28%. Elsewhere, the Dow saw an upswing of 1.02%, while the tech-heavy Nasdaq depreciated by 0.02%.
The stock of biotechnology company has fallen by 9.07% in the past month, lagging the Medical sector's gain of 1.01% and the S&P 500's gain of 0.67%.
The investment community will be paying close attention to the earnings performance of Recursion Pharmaceuticals in its upcoming release. The company is expected to report EPS of -$0.24, up 33.33% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $8.42 million, showing a 62.57% escalation compared to the year-ago quarter.
RXRX's full-year Zacks Consensus Estimates are calling for earnings of -$0.93 per share and revenue of $42.82 million. These results would represent year-over-year changes of +35.42% and -42.66%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Recursion Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.72% downward. Currently, Recursion Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 98, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.